Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
Biankin, Andrew V. 1,2,3,37,40; Waddell, Nicola 4,38; Kassahn, Karin S. 4,38; Gingras, Marie-Claude 5,6; Muthuswamy, Lakshmi B. 7; Johns, Amber L. 1,37; Miller, David K. 4,38; Wilson, Peter J. 4,38; Patch, Ann-Marie 4,38; Wu, Jianmin 1,37; Chang, David K. 1,2,3,37,40; Cowley, Mark J. 1,37; Gardiner, Brooke B. 4; Song, Sarah 4,38; Harliwong, Ivon 4,38; Idrisoglu, Senel 4,38; Nourse, Craig 4,38; Nourbakhsh, Ehsan 4,38; Manning, Suzanne 4,38; Wani, Shivangi 4,38; Gongora, Milena 4,38; Pajic, Marina 1,37; Scarlett, Christopher J. 1,8,37; Gill, Anthony J. 1,9,10,39; Pinho, Andreia V. 1,37; Rooman, Ilse 1,37; Anderson, Matthew 4,38; Holmes, Oliver 4,38; Leonard, Conrad 4,38; Taylor, Darrin 4,38; Wood, Scott 4,38; Xu, Qinying 4,38; Nones, Katia 4,38; Lynn Fink, J. 4,38; Christ, Angelika 4,38; Bruxner, Tim 4,38; Cloonan, Nicole 4,38; Kolle, Gabriel 11; Newell, Felicity 4,38; Pinese, Mark 1,37; Scott Mead, R. 1,12,37; Humphris, Jeremy L. 1,37; Kaplan, Warren 1; Jones, Marc D. 1,37; Colvin, Emily K. 1; Nagrial, Adnan M. 1,37; Humphrey, Emily S. 1; Chou, Angela 1,12,37; Chin, Venessa T. 1,37; Chantrill, Lorraine A. 1,37; Mawson, Amanda 1,37; Samra, Jaswinder S. 9,13,39; Kench, James G. 1,10,14,43; Lovell, Jessica A. 1; Daly, Roger J. 1,37; Merrett, Neil D. 2,15,40; Toon, Christopher 1,39; Epari, Krishna 16; Nguyen, Nam Q. 17,47; Barbour, Andrew 18; Zeps, Nikolajs 19,46; Australian Pancreatic Cancer Genome Initiative; The Kinghorn Cancer Centre, Garvan Institute of Medical Research; Brancato, Mary-Anne L. 37; Rowe, Sarah J. 37; Simpson, Skye L. 37; Martyn-Smith, Mona 37; Thomas, Michelle T. 37; Pettit, Jessica 37; Tao, Jiang 37; DiPietro, Renee 37; Watson, Clare 37; Wong, Rachel 37; Giry-Laterriere, Marc 37; Queensland Center for Medical Genomics, Institute for Molecular Bioscience; Royal North Shore Hospital; Pavlakis, Nick 39; Guminski, Alex 39; Bankstown Hospital; Asghari, Ray 40; Pavey, Darren A. 40; Das, Amitabha 40; Liverpool Hospital; Cosman, Peter H. 41; Ismail, Kasim 41; O'Connor, Chelsie 41; Westmead Hospital; Lam, Vincent W. 42; McLeod, Duncan 42; Pleass, Henry C. 42; Richardson, Arthur 42; James, Virginia 42; Royal Prince Alfred Hospital; Cooper, Caroline L. 43; Joseph, David 43; Sandroussi, Charbel 43; Crawford, Michael 43; Gallagher, James 43; Fremantle Hospital; Texler, Michael 44; Forrest, Cindy 44; Laycock, Andrew 44; Epari, Krishna P. 44; Ballal, Mo 44; Fletcher, David R. 44; Mukhedkar, Sanjay 44; Sir Charles Gairdner Hospital; Spry, Nigel A. 45; DeBoer, Bastiaan 45; Chai, Ming 45; St John of God Healthcare; Beilin, Maria 46; Feeney, Kynan 46; Royal Adelaide Hospital; Ruszkiewicz, Andrew R. 47; Worthley, Chris 47; Tan, Chuan P. 47; Debrencini, Tamara 47; Flinders Medical Centre; Chen, John 48; Brooke-Smith, Mark E. 48; Papangelis, Virginia 48; Greenslopes Private Hospital; Tang, Henry 49; Barbour, Andrew P. 49; Envoi Pathology; Clouston, Andrew D. 50; Martin, Patrick 50; Princess Alexandria Hospital; O'Rourke, Thomas J. 51; Chiang, Amy 51; Fawcett, Jonathan W. 51; Slater, Kellee 51; Yeung, Shinn 51; Hatzifotis, Michael 51; Hodgkinson, Peter 51; Austin Hospital; Christophi, Christopher 52; Nikfarjam, Mehrdad 52; Mountain Victorian Cancer Biobank, Angela 52,53; Johns Hopkins Medical Institutes; Eshleman, James R. 54,25; Schulick, Richard D. 54,26; Wolfgang, Christopher L. 54,26; Morgan, Richard A. 54,25; Hodgin, Mary B. 54; ARC-NET Center for Applied Research on Cancer; Lawlor, Rita T. 55,27; Capelli, Paola 55,28; Beghelli, Stefania 55; Corbo, Vincenzo 55,27; Scardoni, Maria 55,28; Pederzoli, Paolo 55; Tortora, Giampaolo 55,29; Bassi, Claudio 55; University of California, San Francisco; Kakkar, Nipun 5; Zhao, Fengmei 5; Qing Wu, Yuan 5; Wang, Min 5; Muzny, Donna M. 5; Fisher, William E. 6,20; Charles Brunicardi, F. 21; Hodges, Sally E. 6,20; Reid, Jeffrey G. 5; Drummond, Jennifer 5; Chang, Kyle 5; Han, Yi 5; Lewis, Lora R. 5; Dinh, Huyen 5; Buhay, Christian J. 5; Beck, Timothy 7; Timms, Lee 7; Sam, Michelle 7; Begley, Kimberly 7; Brown, Andrew 7; Pai, Deepa 7; Panchal, Ami 7; Buchner, Nicholas 7; De Borja, Richard 7; Denroche, Robert E. 7; Yung, Christina K. 7; Serra, Stefano 22; Onetto, Nicole 7; Mukhopadhyay, Debabrata 23; Tsao, Ming-Sound 22; Shaw, Patricia A. 22; Petersen, Gloria M. 23; Gallinger, Steven 22,24; Hruban, Ralph H. 25,54; Maitra, Anirban 25,54; Iacobuzio-Donahue, Christine A. 25,54; Tempero, Margaret A. 30,56; Mann, Karen M. 31; Jenkins, Nancy A. 31; Perez-Mancera, Pedro A. 32; Adams, David J. 33; Largaespada, David A. 34; Wessels, Lodewyk F. A. 35; Rust, Alistair G. 33; Stein, Lincoln D. 7; Tuveson, David A. 32; Copeland, Neal G. 31; Musgrove, Elizabeth A. 1,36,37; Scarpa, Aldo 27,28,55; Hudson, Thomas J. 7; Sutherland, Robert L. 1,36,58,37; Wheeler, David A. 5; Pearson, John V. 4,38; McPherson, John D. 7; Gibbs, Richard A. 5; Grimmond, Sean M. 4,*,38; Exome sequencing and copy number analysis are used to define genomic aberrations in early sporadic pancreatic ductal adenocarcinoma; among the findings are mutations in genes involved in chromatin modification and DNA damage repair, and frequent and diverse somatic aberrations in genes known as embryonic regulators of axon guidance.
[Article]
Nature.
491(7424):399-405, November 15, 2012.
(Format: HTML, PDF)
: Pancreatic cancer is a highly lethal malignancy with few effective therapies. We performed exome sequencing and copy number analysis to define genomic aberrations in a prospectively accrued clinical cohort (n = 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma. Detailed analysis of 99 informative tumours identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-number variations. We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including additional genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6). Integrative analysis with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis. Pathway-based analysis of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway. We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.
(C) 2012 Nature Publishing Group